{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:58:34Z","timestamp":1791644314339,"version":"4.3.4"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ejmech.2022.114328","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T01:57:07Z","timestamp":1648519027000},"page":"114328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Development of novel dipeptide nitriles as inhibitors of rhodesain of Trypanosoma brucei rhodesiense"],"prefix":"10.1016","volume":"236","author":[{"given":"Carla","family":"Di Chio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santo","family":"Previti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Amendola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Cosconati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute A.","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Schirmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Zappal\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9020-2068","authenticated-orcid":false,"given":"Roberta","family":"Ettari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114328_bib1","unstructured":"Human African Trypanosomiasis (sleeping sickness) https:\/\/www.who.int\/trypanosomiasis_african\/en\/(Accessed January 22 2022)."},{"key":"10.1016\/j.ejmech.2022.114328_bib2","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/S0140-6736(17)31510-6","article-title":"Human african trypanosomiasis","volume":"390","author":"B\u00fcscher","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2022.114328_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001857","article-title":"Stage progression and neurological symptoms in Trypanosoma brucei rhodesiense sleeping sickness: role of the CNS inflammatory response","volume":"6","author":"MacLean","year":"2012","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2022.114328_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1179\/2047773213Y.0000000105","article-title":"A\u00a0current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis","volume":"107","author":"Babokhov","year":"2013","journal-title":"Pathog. Glob. Health"},{"key":"10.1016\/j.ejmech.2022.114328_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"Priotto","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2022.114328_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13071-018-2634-x","article-title":"A\u00a0multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda","volume":"11","author":"Kansiime","year":"2018","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.ejmech.2022.114328_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40265-019-1051-6","article-title":"Fexinidazole: first global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114328_bib8","unstructured":"CHMP recommends first oral-only treatment for sleeping sickness https:\/\/www.ema.europa.eu\/en\/news\/chmp-recommends-first-oral-only-treatment-sleeping-sickness (Accessed January 22 2022)."},{"key":"10.1016\/j.ejmech.2022.114328_bib9","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2174\/1389557515666160509125243","article-title":"The inhibition of cysteine proteases rhodesain and TbCatB: a valuable approach to treat Human African Trypanosomiasis","volume":"16","author":"Ettari","year":"2016","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114328_bib10","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.1021\/jm301424d","article-title":"Inhibition of rhodesain as a novel therapeutic modality for human African trypanosomiasis","volume":"56","author":"Ettari","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114328_bib11","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1172\/JCI27798.","article-title":"Blood-brain barrier traversal by African trypanosomes requires calcium signaling induced by parasite cysteine protease","volume":"116","author":"Nikolskaia","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2022.114328_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-308X(01)49037-3","article-title":"Antigenic variation in trypanosomes: enhanced phenotypic variation in a eukaryotic parasite","volume":"49","author":"Barry","year":"2001","journal-title":"Adv. Parasitol."},{"key":"10.1016\/j.ejmech.2022.114328_bib13","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1515\/BC.2002.077","article-title":"Congopain from Trypanosoma congolense: drug target and vaccine candidate","volume":"383","author":"Lalmanach","year":"2002","journal-title":"Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114328_bib14","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1016\/j.ejmech.2010.04.003","article-title":"Synthesis of novel peptidomimetics as inhibitors of protozoan cysteine proteases falcipain-2 and rhodesain","volume":"45","author":"Ettari","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114328_bib15","first-page":"4928","article-title":"Constrained peptidomimetics as antiplasmodial falcipain-2 inhibitors, Bioorg","volume":"18","author":"Bova","year":"2010","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114328_bib16","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/cmdc.201200274","article-title":"Synthesis and molecular modeling studies of derivatives of a highly potent peptidomimetic vinyl ester as falcipain-2 inhibitors","volume":"7","author":"Ettari","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.114328_bib17","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1002\/cmdc.201300390","article-title":"Development of rhodesain inhibitors with a 3-bromoisoxazoline warhead","volume":"8","author":"Ettari","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.114328_bib18","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1002\/cmdc.201402079","article-title":"Synthesis and biological evaluation of papain-family cathepsin L-like cysteine protease inhibitors containing a 1,4-benzodiazepine scaffold as antiprotozoal agents","volume":"9","author":"Ettari","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.114328_bib19","first-page":"7053","article-title":"Development of novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation, Bioorg","volume":"23","author":"Ettari","year":"2015","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114328_bib20","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1016\/j.bmcl.2016.06.047","article-title":"Development of novel 1,4-benzodiazepine-based Michael acceptors as antitrypanosomal agents","volume":"26","author":"Ettari","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114328_bib21","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3109\/14756366.2015.1108972","article-title":"Synthesis and biological evaluation of novel peptidomimetics as rhodesain inhibitors","volume":"31","author":"Ettari","year":"2016","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114328_bib22","doi-asserted-by":"crossref","first-page":"6911","DOI":"10.1021\/acs.jmedchem.7b00405","article-title":"Development of novel peptide-based Michael acceptors targeting rhodesain and falcipain-2 for the treatment of Neglected Tropical Diseases (NTDs)","volume":"60","author":"Previti","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114328_bib23","doi-asserted-by":"crossref","first-page":"10617","DOI":"10.1021\/acs.jmedchem.9b00908","article-title":"Optimization strategy of novel peptide-based Michael acceptors for the treatment of Human African Trypanosomiasis","volume":"62","author":"Ettari","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114328_bib24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bmcl.2016.11.036","article-title":"Evaluation of dipeptide nitriles as inhibitors of rhodesain, a major cysteine protease of Trypanosoma brucei","volume":"27","author":"Schirmeister","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114328_bib25","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1021\/acs.jmedchem.7b01870","article-title":"2 H-1,2,3-Triazole-based dipeptidyl nitriles: potent, selective, and trypanocidal rhodesain inhibitors by structure-based design","volume":"61","author":"Giroud","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114328_bib26","doi-asserted-by":"crossref","first-page":"127420","DOI":"10.1016\/j.bmcl.2020.127420","article-title":"N-Sulfonyl dipeptide nitriles as inhibitors of human cathepsin S: in silico design, synthesis and biochemical characterization","volume":"30","author":"Lemke","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114328_bib27","article-title":"Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332","author":"Zhao","year":"2021","journal-title":"Protein Cell"},{"key":"10.1016\/j.ejmech.2022.114328_bib28","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114328_bib29","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1002\/chem.201103322","article-title":"Design, synthesis and biological evaluation of potent azadipeptide nitrile inhibitors and activity-based probes as promising anti-Trypanosoma brucei agents","volume":"18","author":"Yang","year":"2012","journal-title":"Chem. Eur. J."},{"key":"10.1016\/j.ejmech.2022.114328_bib30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0166-6851(01)00368-1","article-title":"Active site mapping, biochemical properties and subcellular localization of rhodesain, the major cysteine protease of Trypanosoma brucei rhodesiense","volume":"118","author":"Caffrey","year":"2001","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ejmech.2022.114328_bib31","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.bmcl.2006.02.026","article-title":"Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents","volume":"16","author":"Vicik","year":"2006","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114328_bib32","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1021\/ml400489b","article-title":"Predicting the reactivity of nitrile-carrying compounds with cysteine: a combined computational and experimental study","volume":"5","author":"Berteotti","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114328_bib33","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/cmdc.202000360","article-title":"Peptidyl vinyl ketone irreversible inhibitors of rhodesain: modifications of the P2 fragment","volume":"15","author":"Maiorana","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.114328_bib34","series-title":"Schr\u00f6dinger Release 2021-4","year":"2021"},{"key":"10.1016\/j.ejmech.2022.114328_bib35","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/bip.20968","article-title":"Structure-activity relationship study and NMR analysis of fluorobenzoyl pentapeptide GPR54 agonists","volume":"90","author":"Tomita","year":"2008","journal-title":"Biopolymers"},{"key":"10.1016\/j.ejmech.2022.114328_bib36","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1021\/acs.orglett.7b01068","article-title":"Palladium-catalyzed aminocarbonylation in solid-phase peptide synthesis: a method for capping, cyclization, and isotope labeling","volume":"19","author":"Skogh","year":"2017","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2022.114328_bib37","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0014-827X(98)00038-X","article-title":"Synthesis and aldose reductase inhibitory activity of benzoyl-amino acid derivatives","volume":"53","author":"Benvenuti","year":"1998","journal-title":"Farmaco"},{"key":"10.1016\/j.ejmech.2022.114328_bib38","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/anie.201810470","article-title":"Inhibitor-induced dimerization of an essential oxidoreductase from african trypanosomes","volume":"58","author":"Wagner","year":"2019","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2022.114328_bib39","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3390\/molecules25092064","article-title":"Naphthoquinones as covalent reversible inhibitors of cysteine proteases-studies on inhibition mechanism and kinetics","volume":"25","author":"Klein","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2022.114328_bib40","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2022.114328_bib41","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/pro.2733","article-title":"Covalent docking using autodock: two-point attrsactor and flexible side chain methods","volume":"25","author":"Bianco","year":"2016","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2022.114328_bib42","series-title":"Schr\u00f6dinger Maestro","year":"2020"},{"key":"10.1016\/j.ejmech.2022.114328_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000701","article-title":"Crystal Structures of TbCatB and rhodesain, potential chemotherapeutic targets and major cysteine proteases of Trypanosoma brucei","volume":"4","author":"Kerr","year":"2010","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2022.114328_bib44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jsb.2010.09.007","article-title":"Structural basis for reversible and irreversible inhibition of human cathepsin L by their respective dipeptidyl glyoxal and diazomethylketone inhibitors","volume":"173","author":"Shenoy","year":"2011","journal-title":"J.\u00a0Struct. Biol."},{"key":"10.1016\/j.ejmech.2022.114328_bib45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Sastry","year":"2013","journal-title":"J.\u00a0Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2022.114328_bib46","unstructured":"http:\/\/autodock.scripps.edu\/."},{"key":"10.1016\/j.ejmech.2022.114328_bib47","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1517\/17460441.2010.484460","article-title":"Virtual screening with AutoDock: theory and practice","volume":"5","author":"Cosconati","year":"2010","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114328_bib48","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2022.114328_bib49","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.cpc.2013.12.014","article-title":"Generalized scalable multiple copy algorithms for molecular dynamics simulations in NAMD","volume":"185","author":"Jiang","year":"2014","journal-title":"Comput. Phys. Commun."},{"key":"10.1016\/j.ejmech.2022.114328_bib50","series-title":"Schr\u00f6dinger Release 2020-4: Desmond Molecular Dynamics System, D. E. Shaw Research","year":"2020"},{"key":"10.1016\/j.ejmech.2022.114328_bib51","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1021\/jp003020w","article-title":"Structure and dynamics of the TIP3P, SPC, and SPC\/E water models at 298 K","volume":"105","author":"Mark","year":"2001","journal-title":"J.\u00a0Phys. Chem."},{"key":"10.1016\/j.ejmech.2022.114328_bib52","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1080\/00268979600100761","article-title":"Explicit reversible integrators for extended systems dynamics","volume":"87","author":"Martyna","year":"1996","journal-title":"Mol. Phys."},{"key":"10.1016\/j.ejmech.2022.114328_bib53","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1103\/PhysRevA.31.1695","article-title":"Canonical dynamics: equilibrium phase-space distributions","volume":"31","author":"Hoover","year":"1985","journal-title":"Phys. Rev. A Gen. Phys."},{"key":"10.1016\/j.ejmech.2022.114328_bib54","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","article-title":"OPLS3: a force field providing broad coverage of drug-like small molecules and proteins","volume":"12","author":"Harder","year":"2016","journal-title":"J.\u00a0Chem. Theor. Comput."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422002306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422002306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:39:11Z","timestamp":1759329551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422002306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":54,"alternative-id":["S0223523422002306"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114328","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of novel dipeptide nitriles as inhibitors of rhodesain of Trypanosoma brucei rhodesiense","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114328","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114328"}}